Rameda’s OGM nods to dividends payment
Posted On March 24, 2022
ArabFinance: Tenth of Ramadan for Pharmaceuticals Industries and Diagnostic Reagents (Rameda) (RMDA) announced that its ordinary general meeting (OGM), held on March 22nd, approved the cash dividends’ proposal submitted by the board of directors, according to a statement.
Accordingly, the company shall distribute cash dividends worth EGP 9.607 million, equivalent to EGP 0.0096075 per share, to shareholders for 2021 earnings.
It is worth noting that the company reported a consolidated net profit attributable to the parent company of EGP 181.08 million in 2021, compared to a profit of EGP 112.18 million in 2020.
Rameda is an Egypt-based pharmaceutical company that manufactures both human and veterinary pharmaceuticals.
It operates three fully independent factories at its plant, including 20 production lines capable of producing a wide range of general medicinal forms, namely eye drops, solid dosage forms, syrups, blow-fill-seal, and lyophilized vials, among others.